KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Nektar Therapeutics (NKTR) Return on Invested Capital (2016 - 2025)

Nektar Therapeutics has reported Return on Invested Capital over the past 15 years, most recently at 1.6% for Q4 2025.

  • Quarterly results put Return on Invested Capital at 1.6% for Q4 2025, up 31.0% from a year ago — trailing twelve months through Dec 2025 was 1.6% (up 31.0% YoY), and the annual figure for FY2025 was 1.86%, down 76.0%.
  • Return on Invested Capital for Q4 2025 was 1.6% at Nektar Therapeutics, up from 3.21% in the prior quarter.
  • Over the last five years, Return on Invested Capital for NKTR hit a ceiling of 19.18% in Q2 2025 and a floor of 3.21% in Q3 2025.
  • Median Return on Invested Capital over the past 5 years was 1.29% (2023), compared with a mean of 0.37%.
  • Peak annual rise in Return on Invested Capital hit 2076bps in 2025, while the deepest fall reached -179bps in 2025.
  • Nektar Therapeutics' Return on Invested Capital stood at 0.6% in 2021, then plummeted by -60bps to 0.97% in 2022, then plummeted by -79bps to 1.73% in 2023, then decreased by -11bps to 1.92% in 2024, then rose by 16bps to 1.6% in 2025.
  • The last three reported values for Return on Invested Capital were 1.6% (Q4 2025), 3.21% (Q3 2025), and 19.18% (Q2 2025) per Business Quant data.